Ocrevus (ocrelizumab) is an antibody pharmaceutical. Ocrelizumab was first approved as Ocrevus on 2017-03-28. It is used to treat multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against B-lymphocyte antigen CD20.
|Drug Class||Monoclonal antibodies: humanized, immunomodulating|